Alza
Executive Summary
Unveils two new oral mucosal drug delivery systems, MOTS mucosal oral therapeutic system) for localized delivery and MOSTS system for systemic therapy. Both systems, which are in development, are based on the drug delivery firm's proprietary OROS osmotic pump oral drug delivery system, Alza Co-Chairman and CEO Martin Gerstel told an Alex. Brown health care conference in Baltimore May 8. MOTS/MOSTS overcome disadvantages of previously tried mucosal delivery methods, including lack of "system control" (dosage dumping), short duration of activity, and discomfort or inconvenience, Gerstel said.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.